Jefferies Upgrades Summit Therapeutics to Buy, Raises Price Target to $25

Benzinga · 1d ago
Jefferies analyst Faisal Khurshid upgrades Summit Therapeutics (NASDAQ:SMMT) from Hold to Buy and raises the price target from $15 to $25.